2012-10-06 19:02:44 - New Pharmaceuticals market report from Global Markets Direct: "Tetanus - Pipeline Review, H2 2012"

Global Markets Direct's, 'Tetanus - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Tetanus, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Tetanus. Tetanus - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.


Full Report Details at
- www.fastmr.com/prod/468389_tetanus_pipeline_review_h2_2012.aspx


Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for

the indicated disease.

Scope

* A snapshot of the global therapeutic scenario for Tetanus.
* A review of the Tetanus products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the Tetanus pipeline on the basis of route of administration and molecule type.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.

Reasons to buy

* Identify and understand important and diverse types of therapeutics under development for Tetanus.
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding Tetanus pipeline depth and focus of Indication therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Partial Table of Contents:

Table of Contents
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Tetanus Overview
Therapeutics Development
An Overview of Pipeline Products for Tetanus
Tetanus Therapeutics under Development by Companies
Tetanus Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Tetanus Therapeutics - Products under Development by Companies
Tetanus Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Tetanus Therapeutics Development
Sanofi-Aventis
GlaxoSmithKline plc
Merck & Co., Inc.
Takeda Pharmaceutical Company Limited
Novartis Vaccines and Diagnostics, Inc.
Lipoxen PLC
Green Cross Corporation
LG Life Sciences, Ltd
Panacea Biotec Limited
iBio, Inc.
Tetanus - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
LipoTet - Drug Profile
Product Description
Mechanism of Action
R&D Progress
V501 + Menactra + Adacel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TdaP Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GSK2202083A + Prevenar 13 + Rotarix - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Act-HIB reconstituted with TRIPACEL - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Tdap Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GSK-217744 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DTP-HepB-Polio-Hib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Quadracel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DtwP-HB-Hib (liq) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DTP-HepB/Hib Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Tetanus Toxin Monoclonal Antibody - Drug Profile
Product Description
Mechanism of Action
R&D Progress
V419 + Prevnar 13 + RotaTeq - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Hexaxim - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GC-1107 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Pentavalent DTwP-HepB-Hib Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
KD-332 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Easysix - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TAK-361S - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Acellular Pertussis Vaccine + Tetanus-Diphtheria Booster Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress

Full Table of Contents is available at:
-- www.fastmr.com/catalog/product.aspx?productid=468389&dt=t

About Global Markets Direct

Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. View more research from Global Markets Direct at www.fastmr.com/catalog/publishers.aspx?pubid=1033

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.